[Skip to Content]
[Skip to Content Landing]
February 2, 2011

Carriage of Reduced-Function CYP2C19 Allele Among Patients Treated With Clopidogrel

JAMA. 2011;305(5):467-468. doi:10.1001/jama.2011.77

To the Editor: The meta-analysis by Dr Mega and colleagues shows that among patients treated with clopidogrel for percutaneous coronary intervention, carriage of 1 reduced-function CYP2C19 allele is associated with an increased risk of major adverse cardiovascular events (hazard ratio [HR], 1.55; 95% confidence interval [CI], 1.11-2.17).1 Two methodological issues hamper the interpretation of the results.

First Page Preview View Large
First page PDF preview
First page PDF preview